Business
Update on JV including £20m Funding
Update on JV including £20m Funding.
About this update from Cardiogeni Plc
[{"type":"text","content":"\n\nApril 1st 2025\nCardiogeni PLC\n(\"Cardiogeni\" or the \"Company\")\nUpdate On The Joint Venture Including £20M Funding For The Clinical Development Of Cardiogeni's Portfolio Of Novel Heart Failure Medicines In The United Arab Emirates\n \nCardiogeni (AQSE: CGNI), the UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to advance novel heart failure medicines through human trials, is pleased to provide a progress update on the United Arab Emirates (\"UAE\") joint venture (JV) which includes £20M funding announced on February 10th, 2025.\n \nThe JV negotiation is progressing, with the principal terms described below, being enshrined in a legally binding agreement which is expected to be signed and announced over the coming weeks. \n \nPrincipal Transaction Terms\n· £20m in non-dilutive license funding;\n· £5m of this non-dilutive license funding provided in 2025;\n· formation of a JV corporation to complete development and the commercialisation of Cardiogeni' s medicines in the Gulf Cooperation Council (GCC) states including the UAE, Saudi Arabia, Oman and Bahrain;\n· The JV includes the relevant governmental and family offices sponsorship to expedite the development of Cardiogeni's medicine in the GCC\n \n \nENDS\n \n About Cardiogeni\n \nFounded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group's platform technology enables the creation of unique (living) cells that are engineered with a specific therapeutic function.\n \nThe Group's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. The Group's novel epigenetic cellular reprogramming technology was developed in-house by Professor Sir Martin Evans and the platform along with the pipeline of medicines in development are protected by a portfolio of ~100 international patents and trademarks.\n \nCLXR-001 targets heart failure which will affect 1 in 4 people in their lifetime and is not reversible or curable. CLXR-001 consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regen...